{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T05:37:57Z","timestamp":1720676277154},"reference-count":26,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.lpm.2016.05.007","type":"journal-article","created":{"date-parts":[[2016,5,31]],"date-time":"2016-05-31T17:01:16Z","timestamp":1464714076000},"page":"e205-e210","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"P2","title":["Therapeutic innovations in endocrine diseases \u2013\u00a0Part 2: Modified-release glucocorticoid compounds: What good do they provide to the adrenal insufficient patient?"],"prefix":"10.1016","volume":"45","author":[{"given":"Yves","family":"Reznik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2016.05.007_bib0005","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1210\/jc.2007-0685","article-title":"Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis","volume":"92","author":"Hahner","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2016.05.007_bib0010","doi-asserted-by":"crossref","first-page":"207","DOI":"10.7326\/0003-4819-120-3-199402010-00005","article-title":"Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease","volume":"120","author":"Zelissen","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.lpm.2016.05.007_bib0015","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1046\/j.1365-2265.2003.01761.x","article-title":"Long-term follow-up of bone mineral density in Addison's disease","volume":"58","author":"Jodar","year":"2003","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.lpm.2016.05.007_bib0020","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1055\/s-0033-1351259","article-title":"Increased cardiovascular risk in south african patients with Addison's disease","volume":"45","author":"Ross","year":"2013","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.lpm.2016.05.007_bib0025","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1210\/jc.2006-0524","article-title":"The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients","volume":"91","author":"Filipsson","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2016.05.007_bib0030","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.1210\/jc.2006-0076","article-title":"Premature mortality in patients with Addison's disease: a population-based study","volume":"91","author":"Bergthorsdottir","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2016.05.007_bib0035","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0140-6736(90)91812-O","article-title":"Premature mortality due to cardiovascular diseases in hypopituitarism","volume":"336","author":"Rosen","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2016.05.007_bib0040","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0140-6736(00)04006-X","article-title":"Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group","volume":"357","author":"Tomlinson","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2016.05.007_bib0045","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1046\/j.1365-2265.2002.01466.x","article-title":"Subjective health status in Norwegian patients with Addison's disease","volume":"56","author":"Lovas","year":"2002","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.lpm.2016.05.007_bib0050","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1530\/eje.0.1480449","article-title":"Sleep disturbances in patients with Addison's disease","volume":"148","author":"Lovas","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.lpm.2016.05.007_bib0055","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(03)13492-7","article-title":"Adrenal insufficiency","volume":"361","author":"Arlt","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2016.05.007_bib0060","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1530\/EJE-09-0559","article-title":"Adrenal crisis in treated Addison's disease: a predictable but under-managed event","volume":"162","author":"White","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.lpm.2016.05.007_bib0065","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1530\/EJE-09-0884","article-title":"Epidemiology of adrenal crisis in chronic adrenal insufficiency: the need for new prevention strategies","volume":"162","author":"Hahner","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.lpm.2016.05.007_bib0070","doi-asserted-by":"crossref","first-page":"e0135975","DOI":"10.1371\/journal.pone.0135975","article-title":"PHAD Study Group","volume":"10","author":"Rousseau","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.lpm.2016.05.007_bib0075","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/joim.12162","article-title":"Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency","volume":"275","author":"Husebye","year":"2013","journal-title":"J Intern Med"},{"key":"10.1016\/j.lpm.2016.05.007_bib0080","first-page":"1247","article-title":"The daily cortisol production reinvestigated in healthy men","volume":"83","author":"Kraan","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2016.05.007_bib0085","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2165\/11531290-000000000-00000","article-title":"Pharmacokinetic evidence for suboptimal treatment of adrenal insufficiency with currently available hydrocortisone tablets","volume":"49","author":"Simon","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.lpm.2016.05.007_bib0090","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1365-2265.2004.02106.x","article-title":"Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency","volume":"61","author":"Mah","year":"2004","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.lpm.2016.05.007_bib0095","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1530\/EJE-09-0170","article-title":"Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study","volume":"161","author":"Johannsson","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.lpm.2016.05.007_bib0100","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1210\/jc.2011-1926","article-title":"Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation","volume":"97","author":"Johannsson","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2016.05.007_bib0105","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1530\/EJE-14-0327","article-title":"Prospective evaluation of long-term safety of dual-release hydrocortisone replacement administered once daily in patients with adrenal insufficiency","volume":"171","author":"Nilsson","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.lpm.2016.05.007_bib0110","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1210\/jc.2008-2380","article-title":"Modified-release hydrocortisone to provide circadian cortisol profiles","volume":"94","author":"Debono","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2016.05.007_bib0115","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-2265.2009.03636.x","article-title":"A pharmacokinetic and pharmacodynamic study of delayed \u2013\u00a0and extended\u00a0\u2013 release hydrocortisone (Chronocort) vs. conventional hydrocortisone (Cortef) in the treatment of congenital adrenal hyperplasia","volume":"72","author":"Verma","year":"2010","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.lpm.2016.05.007_bib0120","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/cen.12316","article-title":"An oral multiparticulate, modified-release, hydrocortisone replacement therapy that provides physiological cortisol exposure","volume":"80","author":"Whitaker","year":"2014","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.lpm.2016.05.007_bib0125","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1210\/jc.2014-3809","article-title":"A phase 2 study of Chronocort, a modified-release formulation of hydrocortisone, in the treatment of adults with classic congenital adrenal hyperplasia","volume":"100","author":"Mallappa","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2016.05.007_bib0130","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1210\/jc.2014-4060","article-title":"Development and testing in healthy adults of oral hydrocortisone granules with taste masking for the treatment of neonates and infants with adrenal insufficiency","volume":"100","author":"Whitaker","year":"2015","journal-title":"J Clin Endocrinol Metab"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498216301075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498216301075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T14:58:34Z","timestamp":1536677914000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498216301075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0755498216301075"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2016.05.007","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic innovations in endocrine diseases \u2013\u00a0Part 2: Modified-release glucocorticoid compounds: What good do they provide to the adrenal insufficient patient?","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2016.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2016.05.006","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2016.05.004","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2016.05.010","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2016.05.003","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2016.05.009","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2016.05.005","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2016.05.002","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2016.05.001","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2016.05.008","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}